Most Read Articles
Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
27 Sep 2019
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
Stephen Padilla, 17 Dec 2019
The use of aspirin for primary prevention in patients without known cardiovascular diseases (CVDs) significantly reduces the risk of myocardial infarction (MI) but increases that of major bleeding and haemorrhagic stroke, according to a meta-analysis.

Selpercatinib shows promise in RET-mutant medullary thyroid cancer

24 Sep 2020

Selective RET inhibition with selpercatinib has demonstrated durable efficacy with low-grade toxicity in medullary thyroid cancer patients harbouring RET mutation, according to the results of a phase I–II trial.

The study included three patient cohorts: 55 with RET-mutant medullary thyroid cancer previously treated with vandetanib, cabozantinib, or both (first); 88 with RET-mutant medullary thyroid cancer not previously treated with either drug (second); and 19 with RET fusion–positive previously treated thyroid cancer (third).

Patients who were enrolled in the first phase received selpercatinib at doses ranging from 20 mg once daily to 240 mg twice daily, while those enrolled in the second phase received the recommended dose of 160 mg twice daily. The drug was given orally (capsule or liquid) and continuously, in 28-day cycles, until disease progression, death, unacceptable toxic effects, or withdrawal.

In the first cohort, 69 percent (95 percent confidence interval [CI], 55–81) of patients achieved response (complete or partial). The 1-year progression-free survival was 82 percent (95 percent CI, 69–90).

The respective response and 1-year progression-free survival rates were 73 percent (95 percent CI, 62–82) and 92 percent (95 percent CI, 82–97) in the second cohort, and 79 percent (95 percent CI, 54–94) and 64 percent (95 percent CI, 37–82) in the third cohort.

Common adverse events of grade 3 were hypertension (21 percent), increased alanine aminotransferase level (11 percent), increased aspartate aminotransferase level (9 percent), hyponatremia (8 percent), and diarrhoea (6 percent).

Drug-related adverse events led to treatment discontinuation in 12 patients (2 percent).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
27 Sep 2019
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
Stephen Padilla, 17 Dec 2019
The use of aspirin for primary prevention in patients without known cardiovascular diseases (CVDs) significantly reduces the risk of myocardial infarction (MI) but increases that of major bleeding and haemorrhagic stroke, according to a meta-analysis.